MindMed
MNMD
Market cap $523M

6.42 USD

-0.07

1.08%

At close Oct 17, 4:00 PM EDT

After hours

6.43

+0.01

0.16%

1 day

-1.08%

5 days

24.42%

1 month

5.94%

3 months

-23.48%

6 months

-32.63%

Year to date

77.35%

1 year

118.37%

5 years

-89.35%

About: Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.

Employees: 57

Healthcare Medicinal Chemicals & Botanical Products

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

282% more call options, than puts

Call options by funds: $14.4M | Put options by funds: $3.77M

57% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 28

52% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 25

12% more funds holding

Funds holding: 133 [Q1] → 149 (+16) [Q2]

9% less capital invested

Capital invested by funds: $329M [Q1] → $299M (-$29.1M) [Q2]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]

26.71% less ownership

Funds ownership: 84.51% [Q1] → 57.8% (-26.71%) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$14

118%

upside

Avg. target

$35

445%

upside

High target

$55

757%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Canaccord Genuity Sumant Kulkarni 31% 1-year accuracy 8 / 26 met price target	118%upside $14	Buy Maintained	16 Sept 2024
HC Wainwright & Co. Patrick Trucchio 36% 1-year accuracy 48 / 132 met price target	757%upside $55	Buy Maintained	29 Aug 2024
HC Wainwright & Co. Patrick Trucchio 36% 1-year accuracy 48 / 132 met price target	445%upside $35	Buy Reiterated	31 Jul 2024
Roth MKM Jason Wittes 61% 1-year accuracy 11 / 18 met price target	461%upside $36	Buy Maintained	24 Jul 2024

See Analyst Rankings

Financial journalist opinion

MindMed Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 70,000 common shares of the Company (the "Options"), with an effective grant date of September 9, 2024. The Options have an exercise price eq.

MindMed Announces New Employee Inducement Grants

MindMed to Participate in September Investor Conferences

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: H.C. Wainwright 26th Annual Global Investment Conference Format: Panel Panel Title: Psychedelics in Psychiatry: Breaking New Ground in Mood Disorders Date and Time: Tue.

MindMed to Participate in September Investor Conferences

Psychedelic Stocks: Focus On Their Cash

Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks.

Psychedelic Stocks: Focus On Their Cash

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 PM ET Company Participants Robert Barrow - CEO Daniel Karlin - CMO Reid Robison - Senior Principal Investigator, Cedar Clinical Research Conference Call Participants Elaine Kim - Cantor Fitzgerald Brian Abrahams - RBC Capital Markets Rudy Li - Leerink Partners LLC Daniel Hultberg - Oppenheimer Christopher Chen - Robert W. Baird Sumant Kulkarni - Canaccord Genuity Operator Good morning, and welcome to the Mind Medicine Second Quarter 2024 Financial Results and Corporate Update Conference Call.

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

MindMed readying Phase III trials for LSD therapy to treat anxiety

MindMed Inc. MNMD, -0.87% said Tuesday it's on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through use of lysergide D-tartrate (LSD) in a clinical setting. MindMed is working on FDA approval for an anxiety therapy using LSD.

MindMed readying Phase III trials for LSD therapy to treat anxiety

Pacific Defense Announces US Army CMFF Program Team

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense, a leading provider of Modular Open Systems Approach (MOSA) products and mission solutions, announced their team to compete for the U.S. Army's CMOSS Mounted Form Factor (CMFF) program. Led by Pacific Defense, the CMFF team includes state-of-the-art industry technology leaders Thales Defense & Security Inc., BAE, Regal Technology Partners, Palantir and STC, an Arcfield Company. “Our company is purpose-built to drive the open-systems chang.

Pacific Defense Announces US Army CMFF Program Team

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended June 30, 2024, and provided a business update. “Building on the positive momentum from our Phase 2b data for MM120 ODT in GAD, we are excited to be launching our Phase 3 clinical program in GAD later this year and to announce.

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

The Food and Drug Administration rejected Lykos' application to treat PTSD with MDMA therapy. Atai, Compass Pathways, and MindMed are sliding in the wake of the decision.

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 9,285,511 common shares, without par value, at a public offering price of $7.00 per common share, and, to certain investors, pre-funded warrants to purchase 1,428,775 common shares at a price of $6.999 per pre-funded war.

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

See News Rankings

Charts implemented using Lightweight Charts™